Sanofi (SNY) Competitors & Peers
The 5 largest companies in the same industry as Sanofi, by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| LLY | Peer | $1,146.04 | P/E 38.5RSI 45Cap 1.02 T |
| JNJ | Peer | $269.20 | P/E 31.4RSI 55Cap 652.5 B |
| ABBV | Peer | $264.14 | P/E 74.1RSI 59Cap 466.4 B |
| MRK | Peer | $146.31 | P/E 115.1RSI 50Cap 355.0 B |
| AZN | Peer | $166.84 | P/E 24.5RSI 51Cap 253.6 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- REGNPartner
Regeneron and Sanofi have a massive global collaboration for the development and commercialization of Dupixent and other antibodies.
Model-inferred, unverified — treat as a lead, not evidence - REGNPartner
Sanofi + Regeneron Dupixent + Libtayo immunology collaboration.
Model-inferred, unverified — treat as a lead, not evidence - BPMCMerger
Sanofi $9.5B Blueprint acquisition announced 2025.
Model-inferred, unverified — treat as a lead, not evidence - BPMCPartner
Sanofi $9.5B Blueprint acquisition announced 2025.
Model-inferred, unverified — treat as a lead, not evidence - APGECompetitor
Apogee's APG777 targets the same IL-13 pathway as Sanofi's Dupixent.
Model-inferred, unverified — treat as a lead, not evidence - DNLIPartner
Sanofi partners with Denali to develop RIPK1 inhibitors for multiple sclerosis and Alzheimer's disease.
Model-inferred, unverified — treat as a lead, not evidence - KYMRPartner
Kymera partners with Sanofi to develop and commercialize IRAK4 degraders for immune diseases.
Model-inferred, unverified — treat as a lead, not evidence - CLDXCompetitor
Celldex's barzolvolimab targets similar severe inflammatory skin diseases served by Sanofi's Dupixent.
Model-inferred, unverified — treat as a lead, not evidence